He added that the strong 2014 EPS guidance reflects "strong revenue growth and investment in talent, laboratories, and technologies, particularly in manufacturing, biologics, genomics, R&D, sales and marketing, and information technology as the company continues to expand its services.The majority of Q4 revenue came from WuXi's traditional laboratory-services business, which develops and tests dr